Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).

Miguel Martin,Roberto Hegg,Sung-Bae Kim,Michael Schenker,Daniela Grecea,José A. García-Sáenz,Konstantinos Papazisis,Quchang Ouyang,Aleksandra Łacko,Berna Oksuzoglu,James A. Reeves,Meena Okera,Laura Testa,Chikako Shimizu,Ran Wei,Tammy Forrester,María García Muñoz,Annamaria Zimmermann,Desiree Headley,Stephen R. D. Johnston

Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).

2021

517Background: monarchE, a phase 3, open-label, randomized study evaluating abemaciclib combined with adjuvant endocrine therapy (ET) compared to ET alone in patients with HR+, HER2-, high risk ear...

Keywords:

early breast cancer
Adjuvant
in patient
Oncology
Abemaciclib
Internal medicine
Medicine
Chemotherapy
Randomized controlled trial
endocrine therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations